Hard to study, hard to treat: putting children at the centre of antibiotic research and development

Lancet Infect Dis. 2019 Jun;19(6):573-574. doi: 10.1016/S1473-3099(19)30214-2.

Authors

Manica Balasegaram¹, Bernard Pécoul², Glenda Gray³, Mike Sharland⁴, Soumya Swaminathan⁵

Affiliations

¹ Global Antibiotic Research and Development Partnership, Geneva, Switzerland. Electronic address: [email protected].
² Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
³ South African Medical Research Council, Cape Town, South Africa.
⁴ Institute of Infection and Immunity, St George's University of London, London, UK.
⁵ World Health Organization, Geneva, Switzerland.

PMID: 31122767
DOI: 10.1016/S1473-3099(19)30214-2

No abstract available

MeSH terms

Adolescent
Anti-Bacterial Agents / standards*
Anti-Bacterial Agents / therapeutic use*
Bacterial Infections / drug therapy*
Biomedical Research / standards*
Child
Child, Preschool
Drug Resistance, Microbial*
Evidence-Based Practice / standards*
Female
Guidelines as Topic
Humans
Infant
Infant, Newborn
Male
Patient Selection*
Research Design

Substances

Anti-Bacterial Agents

Grants and funding

001/WHO_/World Health Organization/International